SE440591B - Mineral salt mixture containing selenium - Google Patents
Mineral salt mixture containing seleniumInfo
- Publication number
- SE440591B SE440591B SE8303378A SE8303378A SE440591B SE 440591 B SE440591 B SE 440591B SE 8303378 A SE8303378 A SE 8303378A SE 8303378 A SE8303378 A SE 8303378A SE 440591 B SE440591 B SE 440591B
- Authority
- SE
- Sweden
- Prior art keywords
- selenium
- potassium
- salt mixture
- salt
- magnesium
- Prior art date
Links
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 16
- 239000011669 selenium Substances 0.000 title claims abstract description 16
- 239000011833 salt mixture Substances 0.000 title claims abstract 5
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract 3
- 239000011707 mineral Substances 0.000 title claims abstract 3
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 15
- 239000011780 sodium chloride Substances 0.000 claims abstract description 11
- 235000010755 mineral Nutrition 0.000 claims abstract 2
- 239000011591 potassium Substances 0.000 claims description 12
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 10
- 239000011777 magnesium Substances 0.000 claims description 10
- 229910052749 magnesium Inorganic materials 0.000 claims description 10
- 229910052700 potassium Inorganic materials 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 150000003342 selenium Chemical class 0.000 abstract 1
- 229940091258 selenium supplement Drugs 0.000 description 12
- 239000000047 product Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical group [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940030606 diuretics Drugs 0.000 description 3
- 229910001414 potassium ion Inorganic materials 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000008167 Magnesium Deficiency Diseases 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008233 hard water Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 235000004764 magnesium deficiency Nutrition 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000015598 salt intake Nutrition 0.000 description 2
- 235000021023 sodium intake Nutrition 0.000 description 2
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910052920 inorganic sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229940070017 potassium supplement Drugs 0.000 description 1
- 235000019600 saltiness Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/40—Table salts; Dietetic salt substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
15 20 25 NGÉNâ-'Y viktprocent kalium och 5 - 20 viktprocent magnesium, räknat som fysiologiskt fördragbara föreningar på to- talblandningen. NGÉNâ-'Y% by weight of potassium and 5 to 20% by weight of magnesium, calculated as physiologically tolerable compounds on the total mixture.
Med utgångspunkt från attdagsförbrukning av salt upp- går till cirka 8 - 15 g per dygn, erhålles härigenom ett selenintag på cirka 0,01 - 0,5 mg per dygn.Based on the fact that daily consumption of salt amounts to approximately 8 - 15 g per day, a selenium intake of approximately 0.01 - 0.5 mg per day is thereby obtained.
Många människor intar en alltför stor mängd natrium- klorid och många olika lösningar har diskuterats för att begränsa saltintag och om möjligt dessutom er- hålla en fysiologiskt sett mer optimal fördelning mellan natrium-, kalium-emflumagnesiumjoner i födan.Many people consume an excessive amount of sodium chloride and many different solutions have been discussed to limit salt intake and, if possible, also obtain a physiologically more optimal distribution between sodium, potassium and magnesium ions in the diet.
Härvid har föreshxfits, att en del av natriumjonerna skall ersättas med kaliumjoner, vilket dock leder till en besk smak och en produkt, som inte lämpar sig för användning som t.ex. bordssalt.It has been suggested that some of the sodium ions should be replaced with potassium ions, which, however, leads to a bitter taste and a product which is not suitable for use as e.g. table salt.
Genom att kombinera en i och för sig förut känd pro- dukt innehållande en fysiologiskt optimerad samman- sättning av natrium-, kalium- och magnesiumjoner och eventuellt också kalciumjoner med den enligt uppfinn- ingen angivna mängden selen, erhålles en synnerligen värdefull produkt.By combining a per se known product containing a physiologically optimized composition of sodium, potassium and magnesium ions and possibly also calcium ions with the amount of selenium specified according to the invention, a particularly valuable product is obtained.
Produktens seleninnehåll skall föreligga i biologiskt fördragbar form, och kan därvid föreligga i såväl oor- ganisk som organisk form. Ett exempel på en Oorganisk, fysiologiskt fördragbar selenfördelning är natriumsele- nit. Genom att låta jäst eller gröna ärtor upptaga selen, erhålles selenet i en organisk, biologiskt ned- brytbar form. 10 15 20 30 8303378-'7 Användningen av selen som tillsats i födoämnen har an- setts vara mindre lämplig, då selen i ren form är att betrakta som ett gift. För denna giftverkan krävs emel- lertid relativt stora mängder, och med den selenkoncentra~ tion som föreslås enligt föreliggande uppfinning är det i princip omöjligt att komma upp till denna gräns. I en artikel, publicerad i J. Nutrition, 10, sid 100 - 102 (1950) redogöres för försök med selen som administrerats till råttor. Härvid påvisades en tillväxthämning vid höga doser. Dessutom påvisas att denna tillväxthämmande effekt motverkas av oorganiska sulfater.The selenium content of the product must be in biologically tolerable form, and can be in both organic and organic form. An example of an inorganic, physiologically tolerable selenium distribution is sodium selenite. By allowing yeast or green peas to absorb selenium, selenium is obtained in an organic, biodegradable form. 10 15 20 30 8303378-'7 The use of selenium as an additive in foods has been considered to be less suitable, as selenium in pure form is to be regarded as a poison. For this toxic effect, however, relatively large amounts are required, and with the selenium concentration proposed according to the present invention, it is in principle impossible to reach this limit. In an article, published in J. Nutrition, 10, pages 100 - 102 (1950), experiments with selenium administered to rats are described. A growth inhibition was detected at high doses. In addition, it is shown that this growth inhibitory effect is counteracted by inorganic sulphates.
Genom den enligt uppfinningen föreslagna utföringsformen, där åtminstone någon av jonerna föreligger i form av lätt- lösligt sulfat, har den redan i praktiken obefintliga risken för selenförgiftning ytterligare reducerats.Due to the embodiment proposed according to the invention, in which at least one of the ions is present in the form of easily soluble sulphate, the already non-existent risk of selenium poisoning has been further reduced.
Omfattande undersökningar har bedrivits och bedrives av- seende sambandet mellan natriumintag och olika hjärt- och kärlsjukdomar. Det är en allmänt accepterad uppfattning att vanligt koksalt är den största orsaken till bl.a. högt blodtryck. Trots detta kan man inte se någon generellt avtagande koksaltkonsumtion varför man eftersträvar en ny saltprodukt, med samma selta som vanligt koksalt men med väsentligt reducerat natriuminnehåll. Det har härvid före- slagits att man skall ersätta en del av natriumkloridinne- hållet i vanligt koksalt med kaliumklorid, men trots för- sök att bevisa motsatsen upplever många ett salt med en större mängd natriumklorid utbytt mot kaliumklorid som beskt.Extensive research has been conducted and is being conducted regarding the connection between sodium intake and various cardiovascular diseases. It is a generally accepted view that common table salt is the biggest cause of e.g. Hypertension. Despite this, one can not see any generally declining salt consumption, which is why one strives for a new salt product, with the same saltiness as ordinary common salt but with a significantly reduced sodium content. It has been suggested that a part of the sodium chloride content in ordinary table salt be replaced with potassium chloride, but despite attempts to prove the opposite, many people experience a salt with a larger amount of sodium chloride exchanged for potassium chloride as bitter.
Ytterligare skäl till varför kalium eftersträvas i en dag- ligen använd saltprodukt är att den skyddar mot natriums negativa verkningar, men ett högt natriumintag gör att kalium fälls ut irüunumaoch att kroppen därigenom blir 10 15 20 25 30 8303378-7 ännu fattigare på kalium.Another reason why potassium is sought after in a daily used salt product is that it protects against the negative effects of sodium, but a high sodium intake causes potassium to precipitate and thus the body becomes even poorer in potassium.
Människor som dricker hårt vatten har visat sig ha lägre frekvens av kardiovaskulära sjukdomar. Detta beror på att magnesiuminnehållet i hårt vatten ofta är tillräckligt för att rätta till smärre magnesiumbrister. Det har därför föreslagits att magnesium skall ingå som en del i det dag- ligen använda hushållssaltet.People who drink hard water have been shown to have lower rates of cardiovascular disease. This is because the magnesium content of hard water is often sufficient to correct minor magnesium deficiencies. It has therefore been suggested that magnesium be included as part of the daily salt used.
Behandling med vissa läkemedel, och då särskilt Liazidbase- rad diuretika, ger ofta upphov till magnesiumbrist. För- lust av magnesium och kalium och samtidig retention av kalcium på grund av användningen av tiazidbaserad dio- retika ökar kraftigt risken för hjärtarytmier.Treatment with certain drugs, and especially Liazide-based diuretics, often gives rise to magnesium deficiency. Loss of magnesium and potassium and concomitant retention of calcium due to the use of thiazide-based diuretics greatly increase the risk of cardiac arrhythmias.
Magnesium är nödvändigt för bibehållande av funktionen hos det mitokondriska systemet, vilket ansvarar för upprätt- hållande av cellulärt kalium liksom för de metaboliska processerna. Magnesiumförlust från hjärtat liksom från andra vävnader interfererar med cellmaskineriet utan vil- ket kardiak-kaliumkoncentrationen icke kan upprätthållas.Magnesium is necessary for maintaining the function of the mitochondrial system, which is responsible for maintaining cellular potassium as well as for the metabolic processes. Magnesium loss from the heart as well as from other tissues interferes with the cell machinery without which the cardiac-potassium concentration cannot be maintained.
Magnesiumförluster predisponerar alltså för kaliumförlus- ter och man har till och med föreslagit att patienter som behandlas diuretika bör ges magnesium tillsammans med kaliumsupplement.Magnesium losses thus predispose to potassium losses and it has even been suggested that patients treated with diuretics should be given magnesium together with potassium supplements.
Genom att låta ett vanligt bordssalt innehålla sådana mängder av de fyra jonerna, natrium, kalium, magnesium och kalcium att ett normalt intag ger det dagliga behovet minskar man avsevärt risken för hjärt- och kärlsjukdomar förorsakade av för stort natriumkloridintag och samtidigt ges en möjlighet att fysikaliskt optimera kroppens katjon- balans, och genom att dessutom låta selen ingå erhåller man en direkt verkan mot olika hjärtsjukdomar och samtidigt motverkas förhoppningsvis även uppkomsten av cancer.By allowing a common table salt to contain such amounts of the four ions, sodium, potassium, magnesium and calcium that a normal intake provides the daily need, the risk of cardiovascular disease caused by excessive sodium chloride intake is significantly reduced and at the same time an opportunity is given to physically optimize the body's cation balance, and by also including selenium, you get a direct effect against various heart diseases and at the same time hopefully counteract the onset of cancer.
Claims (1)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8303378A SE440591B (en) | 1983-06-14 | 1983-06-14 | Mineral salt mixture containing selenium |
| AU51642/85A AU584659B2 (en) | 1983-06-14 | 1985-12-24 | Mineral salt mixture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8303378A SE440591B (en) | 1983-06-14 | 1983-06-14 | Mineral salt mixture containing selenium |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8303378D0 SE8303378D0 (en) | 1983-06-14 |
| SE8303378L SE8303378L (en) | 1984-12-15 |
| SE440591B true SE440591B (en) | 1985-08-12 |
Family
ID=20351592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8303378A SE440591B (en) | 1983-06-14 | 1983-06-14 | Mineral salt mixture containing selenium |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU584659B2 (en) |
| SE (1) | SE440591B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2708178B1 (en) * | 1993-07-26 | 1995-10-20 | Midi Salines Est Cie Salins | Composition for salting and preserving foodstuffs and its use. |
| WO1995007630A1 (en) * | 1993-09-17 | 1995-03-23 | Akzo Nobel N.V. | Salt composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI65913C (en) * | 1982-04-07 | 1984-08-10 | Orion Yhtymae Oy | FRAMEWORK FOR FRAMSTAELLNING AV JAERN OCH SELEN INNEHAOLLANDE SPAORAEMNESPREPARAT |
-
1983
- 1983-06-14 SE SE8303378A patent/SE440591B/en not_active IP Right Cessation
-
1985
- 1985-12-24 AU AU51642/85A patent/AU584659B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU5164285A (en) | 1987-06-25 |
| AU584659B2 (en) | 1989-06-01 |
| SE8303378D0 (en) | 1983-06-14 |
| SE8303378L (en) | 1984-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kurtz et al. | Dietary chloride as a determinant of" sodium-dependent" hypertension | |
| CA1134275A (en) | Amino acid solutions for patients with cancers | |
| Kohn et al. | Cardiac arrest and delirium: presentations of the refeeding syndrome in severely malnourished adolescents with anorexia nervosa | |
| US5084482A (en) | Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds | |
| Schrauzer et al. | Selenium in the maintenance and therapy of HIV-infected patients | |
| Levander et al. | Effects of arsenic, mercury, thallium, and lead on selenium metabolism in rats | |
| US7060302B1 (en) | Metal-containing compositions, preparations and uses | |
| AU605512B2 (en) | Pharmaceutical compositions having antineoplastic activity | |
| AT503219B1 (en) | COMBINATION PREPARATION BASED ON ANTIOXIDANTS TO IMPROVE THE SEED QUALITY | |
| US4784852A (en) | Composition for human supply of selenium as trace element | |
| Keating et al. | Folic acid: effect on zinc absorption in humans and in the rat | |
| US20060127499A1 (en) | Vitamin-mineral compositions | |
| HU226984B1 (en) | Medical and food products for treating diabetes mellitus and process for producing thereof | |
| Jones et al. | Relative effectiveness of some compounds for the control of cisplatin-induced nephrotoxicity | |
| US4849220A (en) | Use of boron supplements to increase in vivo production of hydroxylated steroids | |
| US20090060876A1 (en) | Orally Used Compatible Solutes Containing Agents | |
| SE440591B (en) | Mineral salt mixture containing selenium | |
| JP2003246738A (en) | Magnesium-fortification liquid and moisturizer, cosmetic and beverage using this | |
| Tews et al. | Induction of lysine imbalance in rats: relationships between tissue amino acids and diet | |
| Freeman-Narrod et al. | Chronic toxicity of methotrexate in rats: partial to complete protection of the liver by choline: brief communication | |
| Basu et al. | Effects of 5-fluorouracil on the thiamin status of adult female rats | |
| DE29916231U1 (en) | Multivitamin and mineral preparation | |
| Laranjinha et al. | Magnesium supplementation to prevent recurrence of renal stones | |
| EP0003679A1 (en) | Body replacement therapy formula | |
| US4663165A (en) | Method for counteracting the adverse effects of sodium chloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8303378-7 Effective date: 19910131 Format of ref document f/p: F |